BLFS - Biolife Solutions Inc Options
This article provides comprehensive financial data and stock performance metrics for Biolife Solutions Inc. (BLFS), including its last close price, market capitalization, income, sales, key financial ratios, EPS, and insider/institutional ownership details. It also features various performance indicators over different timeframes and analyst recommendations.
Q3 2025 BioLife Solutions Inc Earnings Call Transcript
BioLife Solutions Inc. reported strong Q3 2025 results with a 33% year-over-year increase in cell processing revenue and a 31% increase in total revenue. The company raised its full-year 2025 revenue guidance and improved its balance sheet with a $25 million sale, leading to adjusted EBITDA margin expansion. Despite a decrease in adjusted gross margin due to a one-time inventory reserve and increased GAAP operating expenses, the company maintains a significant presence in the cell and gene therapy landscape.
Does BioLife Solutions’ (BLFS) Russell Value Index Debut Recast Its Cell and Gene Therapy Narrative?
BioLife Solutions (BLFS) was recently added to several Russell value-oriented indices, which is expected to increase its visibility among institutional investors. This inclusion, however, does not alter the company's core strategy of converting embedded products into recurring revenue, nor does it mitigate risks associated with customer concentration and funding pressures in early-stage cell and gene therapy programs. The company's recent Q1 2026 update showed improved earnings, and its future narrative projects significant revenue and earnings growth, suggesting a potential 15% upside to its current price.
BioLife Solutions, Inc.(NasdaqCM:BLFS) added to Russell Microcap Value Benchmark Index
BioLife Solutions, Inc. (NasdaqCM:BLFS), a developer and supplier of cell processing tools and services for the cell and gene therapy market, has been added to the Russell Microcap Value Benchmark Index. The company provides solutions like CryoStor freeze media and HypoThermosol storage media to preserve biologic materials, along with other products such as Sexton cell processing line and CellSeal closed systems. This inclusion indicates increased visibility and recognition within the financial community for BioLife Solutions.
BioLife Solutions, Inc.(NasdaqCM: BLFS) added to Russell 2000 Value Benchmark
BioLife Solutions, Inc. (NasdaqCM: BLFS) has been added to the Russell 2000 Value Benchmark Index, as announced on June 29, 2026. This news follows the company's recent addition to the Russell Microcap Value Benchmark Index. The article also provides recent financial performance, analyst consensus, and a company profile for BioLife Solutions.
BioLife Solutions (BLFS) Joins Multiple Russell Value Indexes At Once
BioLife Solutions (BLFS) has been included in several Russell Value Benchmark indexes, a development likely to influence institutional and index-tracking funds' approach to the stock. The company's shares have shown strong short-term momentum with a 15.0% return over the past month, closing at $28.67, which is about 10.7% below the analyst target and 15.1% below its estimated fair value. This inclusion increases visibility for value-focused and index-tracking funds, though investors should monitor how trading patterns and liquidity evolve as index-related flows can be temporary.
Price to earnings forward of BioLife Solutions, Inc. – NASDAQ:BLFS
This article provides financial information for BioLife Solutions, Inc. (NASDAQ: BLFS), focusing on its price-to-earnings forward metric. The content highlights the company's financial data, market performance on Nasdaq, and general overview within the health technology sector.
Enterprise value to EBITDA forward of BioLife Solutions, Inc. – NASDAQ:BLFS
This article focuses on the enterprise value to EBITDA forward for BioLife Solutions, Inc. (NASDAQ: BLFS). It appears to be a financial data snippet from TradingView, indicating a period, value, and change associated with this financial metric.
Enterprise value to revenue forward of BioLife Solutions, Inc. – NASDAQ:BLFS
This article provides financial information for BioLife Solutions, Inc. (NASDAQ: BLFS), specifically focusing on its enterprise value to forward revenue. It highlights that this data and other financial metrics are available on TradingView, which serves as a platform for market data and analysis.
Biolife Solutions stock hits 52-week high at 29.67 USD
BioLife Solutions Inc. (BLFS) stock reached a new 52-week high of $29.67, with its current trading price at $29.77 and a market capitalization of $1.44 billion. The company has seen a 32.53% increase in stock value over the past year and reported impressive Q1 2026 earnings with 30% revenue growth, exceeding analyst forecasts. Despite these strong results, InvestingPro analysis suggests the stock may be overvalued relative to its fair value.
BioLife Solutions, Inc. Actuals & Estimates (SWB:BJX1)
This article provides detailed financial actuals and analyst estimates for BioLife Solutions, Inc. (SWB: BJX1), covering income statements, balance sheets, cash flow, and valuation metrics. It highlights future price predictions, historical price records, upcoming earnings reports, and recent financial performance data, including revenue, net income, and EBITDA. The company does not currently pay dividends and has 155 employees as of its next earnings date.
Price to book forward of BioLife Solutions, Inc. – LSX:A1XCF2
The article provides financial information for BioLife Solutions, Inc. (A1XCF2) on the Lang & Schwarz Exchange, specifically focusing on its price-to-book forward metric. It appears to be a stub or a section from a larger financial data platform, indicating key financial data points for the company.
Biolife Solutions stock hits 52-week high at 29.67 USD
BioLife Solutions Inc. (BLFS) has reached a new 52-week stock high of $29.67, with its current trading price at $29.77 and a market cap of $1.44 billion. This significant increase of 32.53% over the past year reflects positive investor sentiment, despite being on the "Most Overvalued" list, and is supported by nearly 30% revenue growth in the last twelve months. The company also reported strong Q1 2026 earnings, exceeding revenue forecasts and meeting EPS expectations, further solidifying market confidence.
BioLife Solutions, Inc. Actuals & Estimates (NASDAQ:BLFS)
This article provides key financial actuals and estimates for BioLife Solutions, Inc. (BLFS), including its current stock price, historical performance, analyst forecasts, and recent earnings data. It highlights the company's valuation metrics, revenue, net income, and market capitalization, along with its lack of dividends.
BLFS Forecast — Price Target — Prediction for 2027
BioLife Solutions, Inc. (BLFS) stock currently trades at $27.50, with analysts providing a 1-year price target ranging from $30.00 to $34.00, and a consensus target of $32.30. The company has seen significant stock increases in the past year and expects its next earnings report on August 6, 2026. Despite recent revenue growth, BLFS does not pay dividends and has a negative EBITDA.
Behavioral Patterns of BLFS and Institutional Flows
Biolife Solutions Inc. (NASDAQ: BLFS) is showing weak near and mid-term sentiment, with a neutral long-term outlook. An exceptional 44.4:1 risk-reward short setup is identified, targeting a 13.4% downside with only 0.3% risk. AI models have generated three trading strategies: a Long Position Trading Strategy, a Momentum Breakout Strategy, and a Risk Hedging Short Strategy, emphasizing risk management and optimized position sizing.
BioLife Solutions (BLFS) CFO reports 937-share tax withholding, holds 214K shares
BioLife Solutions CFO Troy Wichterman had 937 shares withheld to cover tax obligations related to the release of restricted stock units. This transaction, valued at $26.04 per share, was a routine tax settlement, not an open-market sale. After the withholding, Wichterman directly holds 214,093 shares of BioLife Solutions common stock.
Form 4 BioLife Solutions Inc For: 22 June By Investing.com
This article from Investing.com reports on a Form 4 filing for BioLife Solutions Inc. dated June 22. It indicates the stock symbol BLFS and notes a 3.15% increase. The content appears to be primarily an announcement of the filing rather than an in-depth analysis.
Form 4 BioLife Solutions Inc For: 22 June By Investing.com
This article from Investing.com reports on a Form 4 filing for BioLife Solutions Inc. dated June 22nd. The content primarily focuses on market data for various indices, commodities, bonds, and shares, indicating the financial context in which the Form 4 information is presented. The article itself is brief and seems to serve as an announcement rather than an in-depth analysis of the Form 4 filing.
BioLife Solutions (BLFS) CEO reports RSU tax share withholding
BioLife Solutions' President and CEO, Roderick De Greef, had 2,775 shares of common stock withheld by the company to cover tax obligations stemming from the release of restricted stock units. This was a non-market transaction for tax purposes, not a sale. Following this withholding, De Greef directly holds 730,971 shares of BioLife Solutions common stock.
Form 4 BioLife Solutions Inc For: 22 June By Investing.com
This article announces the Form 4 filing for BioLife Solutions Inc. on June 22nd. It provides market data, lists trending stocks, and includes sections for popular news and analysis, but contains no further details about the Form 4 filing itself. The content primarily consists of navigational and market information from Investing.com.
[Form 4] BIOLIFE SOLUTIONS INC Insider Trading Activity
BIOLIFE SOLUTIONS INC's Chief Technology Officer, Sean Werner, reported a disposition of 420 shares of Common Stock at $26.04 per share. This transaction was not an open-market trade but shares withheld by the company to cover tax withholding obligations related to restricted stock units. After this event, Werner directly holds 47,831 Common Stock shares.
BioLife Solutions (BLFS) CMO has 470 shares withheld to cover RSU tax bill
BioLife Solutions' Chief Marketing Officer, Todd Berard, had 470 shares of common stock withheld by the company to cover tax obligations related to the vesting of his restricted stock units (RSUs). This transaction, which is a tax-withholding disposition and not an open-market sale, left Berard with 162,942 direct shares of BioLife Solutions common stock. The withheld shares were valued at $26.04 per share.
BioLife Solutions (BLFS) Stock Could Be 19.7% Undervalued After Portfolio Re Entry
BioLife Solutions (BLFS) has been re-added to Prosper Stars & Stripes' portfolio, highlighting its focus on biopreservation and cell/gene therapy. The stock has seen significant short-term gains, with analysts suggesting it could be 19.7% undervalued at $32.44 compared to its current price of $26.04. However, despite potential undervaluation based on future growth narratives, the company faces risks from customer concentration and falling gross margins, and its Price/Sales ratio of 12.5x makes it appear expensive relative to its industry and peers.
BioLife Solutions Inc (BLFS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a brief overview of BioLife Solutions Inc (BLFS), including its stock price, market cap, and a partial revenue breakdown. The revenue breakdown shows regional contributions for recent periods, with the United States accounting for 80% of revenue, Europe & Middle East & Africa (EMEA) for 14%, and other countries for 6%. Information regarding revenue by business segment was not disclosed by the company.
BioLife Solutions Inc (BLFS) Earnings Forecast: Future EPS & Revenue Growth Estimates
BioLife Solutions Inc (BLFS) has an earnings forecast score of 8.40, placing it 37th in the Healthcare Equipment & Supplies industry. Analysts have an average price target of $32.00 for the company, with a "Buy" rating based on the consensus of 10 analysts. The company's expected revenue for the next quarter is $27.57 million, and EPS for the next quarter is projected at $0.03.
What Makes BioLife Solutions (BLFS) a Compelling Long-Term Hold?
Prosper Stars & Stripes, a long/short equity fund, discussed BioLife Solutions, Inc. (BLFS) in its Q1 2026 investor letter, highlighting its transformation under current CEO Roderick de Greef. The company, focused on biopreservation media for the cell and gene therapy industry, is seen as a compelling long-term opportunity due to its cleaner business, strong growth prospects in its end markets, and favorable valuation. Despite underperforming the Russell 2000, the fund believes BLFS offers a strong risk/reward at current levels.
BioLife Solutions Inc (BLFS) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of BioLife Solutions Inc (BLFS), outlining major institutional holders and their respective proportions. It also presents data on shareholder types, showing the dominant role of investment advisors and hedge funds, and tracks institutional shareholding changes over several quarters.
BioLife Solutions Inc (BLFS) Institutional Confidence
BioLife Solutions Inc (BLFS) has an institutional shareholding score of 10.00, placing it first in the Healthcare Equipment & Supplies industry. Institutional shareholding decreased by 3.89% quarter-over-quarter, now at 105.07%. The largest institutional holder is Bill Nygren | OAKMX, with a 1.20% stake and a 1900% increase in holdings.
BioLife Solutions Inc (BLFS) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides details on the dividend and stock split history for BioLife Solutions Inc (BLFS). It notes that the company has distributed $0.00 USD in dividends over the past five years and shows no record of stock splits. The page also includes current stock performance metrics and market capitalization for BLFS.
Should You Think About Buying BioLife Solutions, Inc. (NASDAQ:BLFS) Now?
This article discusses BioLife Solutions, Inc. (NASDAQ:BLFS) and whether it is a good time to consider buying its stock. It likely analyzes the company's current financial situation, market position, and future prospects to provide investment insights for potential buyers.
(BLFS) Movement Within Algorithmic Entry Frameworks
Biolife Solutions Inc. (NASDAQ: BLFS) is showing neutral near-term sentiment with mid-term strong sentiment potentially stalling, according to Stock Traders Daily's AI analysis. The report highlights resistance testing, a significant short setup with a 45.1:1 risk-reward ratio, and provides three distinct trading strategies: Position Trading, Momentum Breakout, and Risk Hedging. Multi-timeframe signal analysis also details support and resistance levels across near-term, mid-term, and long-term horizons.
BioLife Solutions, Inc. (BLFS) tops Q1 earnings and revenue estimates
BioLife Solutions, Inc. (BLFS) exceeded both earnings and revenue estimates for the first quarter. The company reported a net loss of $0.09 per share, outperforming the analyst consensus of a $0.23 loss, and achieved revenues of $25.99 million, surpassing the $25.32 million estimate. This positive performance suggests strong operational execution and market reception for BioLife Solutions' offerings.
BioLife Solutions, Inc. (BLFS) tops Q1 earnings and revenue estimates
BioLife Solutions, Inc. (BLFS) exceeded both earnings and revenue estimates for the first quarter. The company reported adjusted earnings of $0.09 per share, surpassing the Zacks Consensus Estimate of $0.07 per share, and achieved revenues of $36.03 million, which also beat expectations and represented a significant year-over-year increase. This strong performance highlights an optimistic outlook for the company's financial health.
[Form 4] BIOLIFE SOLUTIONS INC Insider Trading Activity
BioLife Solutions Inc.'s Chief Marketing Officer, Todd Berard, reported a tax-related disposition of 356 shares of Common Stock to cover tax withholding obligations upon the release of restricted stock units. This transaction does not represent an open-market sale, and Berard's direct holdings remain largely unchanged at 163,412 shares. The filing, a Form 4, indicates a neutral impact and sentiment regarding the insider trading activity.
BioLife Solutions (BLFS) CFO reports 1,026-share tax withholding, retains 215,030
BioLife Solutions CFO Troy Wichterman reported a routine tax-related disposition where 1,026 shares of common stock were withheld to cover tax obligations from vested restricted stock units. This transaction was not an open-market sale, and Wichterman retains a substantial equity position, holding 215,030 shares of BioLife Solutions common stock. The event reflects a compensation-related, non-discretionary transaction.
BIOLIFE SOLUTIONS (BLFS) EVP has 627 shares withheld to cover RSU taxes
BIOLIFE SOLUTIONS INC's EVP & Chief Scientific Officer, Mathew Aby J., had 627 common shares withheld on June 8, 2026, at $26.10 per share. This transaction was a routine tax-withholding disposition to cover obligations arising from the release of restricted stock units, not an open-market sale. Following this event, Mathew Aby J. directly holds 389,540 shares of common stock.
BioLife Solutions Leads 3 Stocks Estimated To Be Trading Below Fair Value
The US market has increased by 26% over the past year, and this article highlights three undervalued stocks based on cash flows: BioLife Solutions (BLFS), LPL Financial Holdings (LPLA), and Reddit (RDDT). Each company is trading at a significant discount to its estimated fair value and is projected to have strong future earnings growth. Detailed analyses for each stock are provided, including current price, fair value, and growth forecasts.
[SCHEDULE 13G] BIOLIFE SOLUTIONS INC Passive Investment Disclosure (>5%)
Casdin Capital, LLC and affiliated entities have filed a Schedule 13G, disclosing a shared beneficial ownership of 4,757,165 shares of BioLife Solutions Inc. (BLFS) common stock, representing 9.7% of the class. The filing, dated June 4, 2026, indicates that these shares are held by advisory clients, including Casdin Partners Master Fund, L.P., and that the reporting persons disclaim sole voting or dispositive power. The disclosure highlights a passive investment stake, not intended for control.
BioLife Solutions (BLFS) 10K Form and Latest SEC Filings 2026
MarketBeat provides an overview of BioLife Solutions' (BLFS) SEC filings, noting over 1,006 documents submitted since 2017. The article details recent filings such as a Form SCHEDULE 13G on June 4, 2026, a Form 4 on May 21, 2026, and an 8-K on June 3, 2026. It also explains the significance of different SEC filing types like 10-K, 10-Q, 8-K, and Form 4 for investors.
BioLife Solutions issues investor presentation, cites $96M FY2025 revenue and 17-20% 2026 guidance
BioLife Solutions issued an investor presentation, projecting $96 million in revenue for FY2025 with 29% organic growth and a 26% adjusted EBITDA margin. The company forecasts 17-20% revenue growth for 2026, expecting positive GAAP net income and continued adjusted EBITDA expansion. BioLife Solutions highlights its market leadership, with products used in over 70% of clinical trials and approximately 90% of commercially relevant FDA-approved cell therapies.
BioLife Solutions (NASDAQ: BLFS) guides to 17–20% revenue growth and GAAP profitability in 2026
BioLife Solutions (NASDAQ: BLFS) provided an investor presentation forecasting 17-20% revenue growth and GAAP profitability for 2026, building on a strong pro forma 2025 performance of $96.2 million revenue and a 29% year-over-year increase. The company, a leading provider of biopreservation and cell processing tools for cell-based therapies, reported a 65% gross margin and 26% adjusted EBITDA margin in 2025. BioLife's products are widely adopted in over 950 global clinical trials and 90% of commercially approved cell-based therapies, underscoring its significant market position and expected continued growth in the cell-based therapy market.
HC Wainwright Has Pessimistic Outlook of BLFS Q2 Earnings
HC Wainwright has revised its Q2 2026 EPS estimate for BioLife Solutions (NASDAQ:BLFS) from $0.01 to ($0.02), indicating a more cautious stance on the company's near-term profitability. Despite this, BioLife Solutions recently surpassed Q1 estimates with $0.04 EPS and $27.5 million in revenue, leading to a 6.9% stock increase. The stock currently holds a "Hold" consensus rating among analysts, with a target price of $32.00.
10 Health Care Stocks With Whale Alerts In Today's Session
This article identifies 10 healthcare stocks that are showing "whale alerts" based on unusual options activity in today's trading session. Whale alerts indicate significant transactions by large investors, which can suggest potential shifts in market sentiment or future price movements. The report details specific call and put options activity, including strike prices, expiration dates, and sentiment (bullish or bearish) for companies like Tempus AI, Mesoblast, Charles River Laboratories, and Eli Lilly.
Activist Interest Puts Spotlight On BioLife Solutions Valuation And Momentum
Activist investors have disclosed involvement in BioLife Solutions (BLFS), drawing attention to the company's strategy and valuation. The stock trades below analyst targets and estimated fair value, but significant insider selling has occurred alongside a recent 24.7% monthly gain. Investors should monitor developments from activist engagement and potential changes in governance or capital allocation.
Analysts Offer Insights on Healthcare Companies: BioNano Genomics (BNGO) and BioLife Solutions (BLFS)
This article highlights bullish sentiments from analysts for two healthcare companies: BioNano Genomics (BNGO) and BioLife Solutions (BLFS). Maxim Group maintained a Buy rating for BioNano Genomics with a $4.00 price target, while H.C. Wainwright reiterated a Buy rating for BioLife Solutions with a $32.00 price target. The article includes analyst star rankings and average returns.
BioLife Solutions (Nasdaq:BLFS) - Stock Analysis
BioLife Solutions (BLFS) is analyzed as trading below its estimated fair value, with strong forecasted earnings growth of 50.38% per year. The company is transitioning to profitability, with recent Q1 2026 earnings exceeding analyst expectations, driven by demand for its CryoStor biopreservation media. Despite significant insider selling over the past three months and a history of share dilution, analysts generally agree on a positive future price movement for the stock.
BioLife Solutions coming to Noblesville
BioLife Solutions, a life science company, will relocate its headquarters from Indianapolis to Washington Business Park in Noblesville, investing $16 million in a new 40,000-square-foot facility. The move is expected to retain 20 jobs and create 10 new full-time jobs, with incentives from the city including tax abatements and a forgivable loan. Noblesville leadership anticipates this relocation will bring innovation and high-wage jobs, supporting the community's long-term economic vitality.
Casdin discloses 9.7% BioLife Solutions stake (NASDAQ: BLFS)
Casdin Capital and its affiliates have disclosed a 9.7% beneficial ownership stake in BioLife Solutions (NASDAQ: BLFS), totaling 4,757,165 common shares. The stake was acquired for investment purposes using the fund's working capital, without specific borrowing. While currently having no concrete plans for corporate changes, Casdin reserves the right to engage with management and other shareholders to maximize shareholder value and may adjust its holdings in the future.
[Form 4] BIOLIFE SOLUTIONS INC Insider Trading Activity
A recent Form 4 filing indicates significant insider selling activity for BioLife Solutions Inc. (BLFS) by Casdin Partners Master Fund, L.P. The fund sold a total of 1.2 million shares of common stock across three transactions from May 19 to May 21, 2026, at prices ranging from $22.65 to $23.70. Despite these sales, Casdin Partners Master Fund still retains a substantial indirect holding of 4,757,165 shares in BLFS.
